Therefore, the co-dependency of KCNMA1 and p-BRAF is highlighted as critical for BRAF-mutated glioma progression and, due to this, KCNMA1 could be a valuable potential therapeutic drug target for the treatment of tumors with BRAF mutations. The gene discussed is KCNMA1; the disease is glioma.